Advertisement
Advertisement

MCRB

MCRB logo

Seres Therapeutics, Inc.

14.84
USD
Sponsored
-0.44
-2.88%
Jan 30, 15:59 UTC -5
Closed
exchange

After-Market

14.86

+0.02
+0.13%

MCRB Earnings Reports

Positive Surprise Ratio

MCRB beat 19 of 40 last estimates.

48%

Next Report

Date of Next Report
Mar 11, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$2.17
Implied change from Q3 25 (Revenue/ EPS)
-100.00%
/
-330.85%
Implied change from Q4 24 (Revenue/ EPS)
--
/
+8.50%

Seres Therapeutics, Inc. earnings per share and revenue

On Nov 05, 2025, MCRB reported earnings of 0.94 USD per share (EPS) for Q3 25, missing the estimate of 1.30 USD, resulting in a -28.00% surprise. Revenue reached 351.00 thousand, compared to an expected --, with a 0.00% difference. The market reacted with a -7.64% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 analysts forecast an EPS of -2.17 USD, with revenue projected to reach -- USD, implying an decrease of -330.85% EPS, and decrease of -100.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
For Q3 2025, Seres Therapeutics, Inc. reported EPS of $0.94, missing estimates by -28%, and revenue of $351.00K, 0% as expectations.
The stock price moved down -7.64%, changed from $13.75 before the earnings release to $12.70 the day after.
The next earning report is scheduled for Mar 11, 2026.
Based on 5 analysts, Seres Therapeutics, Inc. is expected to report EPS of -$2.17 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement